The relationship between HIV and substance use has long been understood as one of compounding harm. Now, new research is beginning to map exactly how that harm operates at the level of individual brain cells, and what it means for treatment. “The intersection of HIV and substance use continues to shape research priorities at NIDA,” said Dr Nora Volkow, Director of the National Institute on Drug Abuse. “One of these priorities is to create bridges across the research continuum that can advance effective, evidence-based HIV and substance use interventions across biological, clinical and structural levels.”

The latest work emerging from NIDA-supported programmes represents some of the most precise science yet conducted on how drugs and HIV interact inside the human brain.

A Syndemic With Serious Consequences

HIV and drug addiction are sometimes described together as a syndemic, meaning two crises so intertwined that addressing one without the other produces limited results. Drug intoxication can impair judgement and raise impulsivity, increasing exposure to situations that elevate the risk of HIV transmission. Drug use can also weaken immune function and reduce engagement with health care, accelerating both transmission and disease progression.

Recent HIV clusters in the United States have consistently involved overlapping factors: housing instability, limited access to care, psychosocial stressors, and injection drug use. The picture that emerges is not one of isolated risk behaviours but of structural conditions that make harm far more likely.

What Is Happening Inside the Brain

A study conducted through NIDA’s SCORCH programme (Single Cell Opioid Responses in the Context of HIV) used single-cell sequencing of human brain tissue to examine how individual cell types respond to both HIV and substance use disorders. The findings shift the understanding of HIV’s neurological impact considerably.

Researchers at the Icahn School of Medicine at Mount Sinai found that while neurons themselves are not directly infected by HIV, they show significant changes in gene activity linked to stress, inflammation and disrupted signalling. The virus, it appears, damages brain function indirectly. At the same time, microglia, the brain’s resident immune cells and a key site of HIV persistence, showed heightened inflammatory responses that contribute to ongoing neural injury and may help sustain viral reservoirs in the brain.

Critically, substance use amplifies many of these same pathways. HIV and drugs like opioids or cocaine interact within specific populations of neurons in ways that can worsen cognitive impairment, reinforce addiction-related circuitry, and complicate both treatment and long-term health outcomes.

The value of this research is its precision. Rather than broad observations about HIV and substance use, these findings identify specific cellular targets for therapies that could reduce brain inflammation, protect neural function, and disrupt HIV’s persistence in the central nervous system.

The Criminal Justice Gap

Research at the cellular level matters. So does the question of who actually receives treatment, and under what conditions.

NIDA’s CONNECT programme, launched in 2024, addresses one of the most significant gaps in HIV and substance use care: people involved in the criminal justice system. This population faces disproportionately high rates of both HIV and substance use disorders, combined with fragmented care that tends to break down at precisely the moments of greatest vulnerability, particularly during reentry into the community after incarceration.

CONNECT brings together researchers, service providers, people with lived experience, and criminal justice partners to test scalable models that integrate prevention, diagnosis and treatment with evidence-based substance use disorder services. Eight regional research hubs are conducting trials across high-burden communities. A patient engagement resource centre ensures the research reflects the experiences of those most affected.

The goal is not simply to generate findings but to build the infrastructure needed to sustain better care over time.

What the Evidence Points To

NIDA has been one of the largest funders of HIV research at the National Institutes of Health for decades. That investment established foundational principles that now shape global care: that medications for opioid use disorder are an essential component of HIV treatment, and that delivering HIV treatment to people who inject drugs reduces viral load and transmission across entire communities.

The current generation of research builds on those foundations, moving from population-level outcomes to cell-level mechanisms, and from clinical trials to real-world implementation in the settings where people actually live and seek care.

Ending the HIV epidemic will require addressing HIV prevention and treatment, substance use disorders, and the structural conditions that drive risk, simultaneously and in coordination. The science increasingly shows why that integration is not optional.

Source: NIDA